How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,198 results for

Thrombin Hemostatic

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

321. Haemostasis and Tranexamic Acid in Caesarean Delivery

for women with activated fibrinolysis. The aim of the ancillary biologic study BIO-TRAAP is thus to explore haemostasis and fibrinolysis in peripartum, to determine which women will in the future benefit from TXA. Fibrinolysis will be studied by clot lysis time by Global Fibrinolytic Capacity test on the Lysis Timer (GFC/LT), t-PA, PAI-1, PAI-2, euglobulin clot lysis time, plasminogen, plasmin-anti-plasmin complex, thrombin-anti-thrombin complex, fibrin degradation products (FDP). Study Design Go (...) , and Time 120min ] Fibrinogen (g/l) Fibrin degradation products [ Time Frame: Baseline, Time 15min, and Time 120min ] Fibrin degradation products (µg/l) Plasmin-antiplasmin complex [ Time Frame: Baseline, Time 15min, and Time 120min ] Plasmin-antiplasmin complex (µg/l) Thrombin-antithrombin complex [ Time Frame: Baseline, Time 15min, and Time 120min ] Thrombin-antithrombin complex (ng/ml) Bleeding [ Time Frame: Baseline, Time 15min, and Time 120min ] Bleeding (ml) Transfusion of packs of red blood cells

2018 Clinical Trials

322. Argatroban Plus R-tPA for Acute Ischemic Stroke

or diastolic pressure ≥110 mmHg; Platelet count < 105/mm3; Heparin therapy or oral anticoagulation therapy within 48 hours; Abnormal APTT; Thrombin or Xa factor inhibitor; Severe disease with a life expectancy of less than 3 months; Blood glucose < 50 mg/dL (2.7mmol/L); Patients who have received any other investigational drug or device within 3 months; Pregnancy; Researchers consider patients inappropriate to participate in the registry. Contacts and Locations Go to Information from the National Library (...) Mechanisms of Pharmacological Action Antithrombins Serine Proteinase Inhibitors Protease Inhibitors Enzyme Inhibitors Anticoagulants Platelet Aggregation Inhibitors Hemostatics Coagulants

2018 Clinical Trials

323. Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro. Full Text available with Trip Pro

Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro. Essentials Emicizumab mimics factor (F)VIIIa cofactor function, augments the intrinsic tenase activity. We assessed the emicizumab-driven hemostatic function in FXI-deficient plasmas. Emicizumab improved the coagulation potentials in severe FXI-deficient plasma. Emicizumab may provide a possibility for clinical application in patients with FXI deficiency (...) . SUMMARY: Background Patients with factor (F)XI deficiency commonly present with markedly prolonged activated partial thromboplastin times (APTT), although bleeding phenotypes are heterogeneous. Emicizumab, a bispecific monoclonal antibody to FIX/FIXa and FX/FXa, mimics FVIIIa cofactor function on phospholipid (PL) surfaces. Antibody reactions were designed, therefore, to augment mechanisms during the propagation phase of blood coagulation. Aim To assess emicizumab-driven hemostatic function in FXI

2018 Journal of Thrombosis and Haemostasis

324. Comparison of the Efficacy & Safety of Resusix With FP24 in Patients With Acquired Coagulopathy

in bleeding score in patients with active bleeding [ Time Frame: 120 minutes ] Measured as excellent, good or poor Thrombin generation [ Time Frame: 72 hours ] Measured in nM Serology for human immunodeficiency virus [ Time Frame: 95 days ] Measured in IU/mL Serology for hepatitis [ Time Frame: 95 days ] Measured in IU/mL Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family (...) : February 25, 2019 Last Verified: February 2019 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Blood Coagulation Disorders Hemostatic Disorders Hematologic Diseases Vascular Diseases Cardiovascular Diseases Hemorrhagic Disorders

2018 Clinical Trials

325. Trial of PCC Versus FFP in Patients Undergoing Heart Surgery

is delegated to the Chief Investigator. Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Queen Mary University of London: fresh frozen plasma prothrombin complex concentrate cardiac surgery Additional relevant MeSH terms: Layout table for MeSH terms Thrombin Hemostatics Coagulants

2018 Clinical Trials

326. In vitro comparison of the hemocompatibility of two centrifugal left ventricular assist devices. (Abstract)

In vitro comparison of the hemocompatibility of two centrifugal left ventricular assist devices. Shear stress from left ventricular assist devices induces von Willebrand factor degradation and platelet dysfunction, leading to nonsurgical bleeding. We characterized the hemostatic changes induced by 2 centrifugal left ventricular assist devices, the HeartMate 3 (Abbott Inc, Chicago, Ill) and the EVAHEART (Evaheart Inc, Houston, Tex), for comparison.Whole blood from 8 healthy volunteers was used (...) /min, EVAHEART = 100 mL/min). A panel of coagulation markers was analyzed to investigate hemostatic changes.The free plasma hemoglobin concentration was significantly lower in the EVAHEART compared with the HeartMate 3 after 6 hours of mock-loop circulation under both settings (optimal: 37 ± 31 vs 503 ± 173 mg/dL, P < .0001; equal: 27 ± 4 vs 139 ± 135 mg/dL, P = .024). Loss of von Willebrand factor high-molecular-weight multimers occurred in both left ventricular assist devices and settings

2018 Journal of Thoracic and Cardiovascular Surgery

327. Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Subjects

table for MeSH terms Hemostatics Thrombin Fibrin Tissue Adhesive Coagulants (...) surgery in pediatric subjects. Pediatric subjects (<18 years of age) requiring an elective (non-emergent), open (non-laparoscopic), pelvic, abdominal, or thoracic (non-cardiac) surgical procedure, wherein a target bleeding site (TBS) is identified, and a topical hemostatic agent is indicated, will be eligible to participate in the clinical trial. The study treatments will be applied on the cut parenchymous surface of a solid organ (ie, liver) and in soft tissue (ie, fat, muscle, or connective tissue

2018 Clinical Trials

328. Study of Hemostasis in Patients With Congenital Disorder of Glycosylation

, although stroke-like episodes, the most frequent event, were not analyzed in this study. Moreover, the hemostatic balance is usually investigated by global coagulation tests such as the prothrombin time (PT) and the activated partial thromboplastin (aPTT). However, these tests have serious limitations. First, they explore only 5 % of the whole generated thrombin, enough to clot the plasma. In addition, global tests are insensitive to the coagulation inhibitors, especially the PC system which cannot (...) Pathologic Processes Carbohydrate Metabolism, Inborn Errors Metabolism, Inborn Errors Genetic Diseases, Inborn Metabolic Diseases Thrombin Hemostatics Coagulants

2018 Clinical Trials

329. Rôle of the Soluble Endothelial Protein C Receptor in Cirrhosis-associated Hypercoagulability State (EXERCISE)

a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by University Hospital, Clermont-Ferrand: cirrhosis hypercoagulability thrombin generation assay soluble Endothelial Protein C Receptor Additional relevant MeSH terms: Layout table for MeSH terms Fibrosis Liver Cirrhosis Thrombophilia Pathologic Processes Liver Diseases Digestive System Diseases Hematologic Diseases Thrombin Protein C Hemostatics Coagulants Anticoagulants Fibrinolytic Agents (...) to this imbalance are unclear. Studies need to be completed to improve patient's management. The EPCRs (Endothelial Protein C Receptor soluble) takes part in blood coagulation process. Previous studies have shown that blood levels of EPCRs are increased in patients with cirrhosis. The primary purpose of the study is to evaluate if the EPCRs could play a role in cirrhosis-associated hypercoagulability state. Condition or disease Intervention/treatment Phase Cirrhosis Biological: Thrombin generation assay

2018 Clinical Trials

330. Blood-saving Effect of Combined Intravenous Tranexamic Acid With Topical Floseal® Application Total Hip Arthroplasty

for allogenic blood transfusion. Tranexamic acid (TXA) was reportedly effective reducing total blood loss (TBL) after standard THA. However, a TBL of one L is still high for elderly patients. Floseal (Baxter, Deerfield, Illinois), a thrombin-based hemostatic agent, have been widely used in surgical procedure. However, there is no study investigating the effect of Floseal in THA procedures.This study anticipated that combination with the two different mechanism of topical hemostatic agent, Floseal (...) a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Wang Jun-Wen, Chang Gung Memorial Hospital: Total hip arthroplasty Tranexamic acid Floseal postoperative blood loss Thrombin Additional relevant MeSH terms: Layout table for MeSH terms Tranexamic Acid Hemostatics Antifibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Coagulants

2018 Clinical Trials

331. Topical rhThrombin as an Adjunct to Hemostasis During Segmental Hepatectomy

hepatectomy; The second part:rhThrombin ( Topical ) 1000IU/m and 2000IU/ml with absorbable collagen sponge During segmental hepatectomy; The third part:rhThrombin ( Topical ) 1000IU/m and 2000IU/ml used directly sprayed on hemorrhagic point During segmental hepatectomy; Drug: rhThrombin ( Topical ) Active Substance Other Name: Recombinant Human Thrombin (CHO Cell) for Topical Use Placebo Comparator: placebo The first part: the same volume of saline during segmental hepatectomy; The second part:the same (...) : From start of treatment until 6 minutes after treatment start ] Subjects achieving hemostasis at the target bleeding site by 6 minutes following the start of treatment without the occurrence of re-bleeding until the completion of surgical closure The hemostatic time of the woud [ Time Frame: From start of treatment until 6 minutes after treatment start ] The hemostatic time of the woud immunogenicity [ Time Frame: Time Frame: baseline to 4 weeks ] Incidence of rhThrombin antibody and Confirm

2018 Clinical Trials

332. Thromboelastometry-identified Haemostatic Changes in Isolated Traumatic Brain Injury

adding more. Thromboelastometry-identified Haemostatic Changes in Isolated Traumatic Brain Injury (THROMBIN) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03616808 Recruitment Status : Recruiting First Posted : August 6 (...) , 2018 Last Update Posted : August 22, 2018 See Sponsor: Lithuanian University of Health Sciences Information provided by (Responsible Party): MARIUS RIMAITIS, Lithuanian University of Health Sciences Study Details Study Description Go to Brief Summary: A prospective open-label case-control study will be performed aiming to assess the utility of thromboelastometry (ROTEM) for identification of hemostatic changes, goal-directed coagulation management, and prognosis of intracranial hemorrhagic injury

2018 Clinical Trials

333. Human platelets express Endothelial Protein C Receptor which can be utilized to enhance localization of Factor VIIa activity. Full Text available with Trip Pro

therapeutics.Background High-dose factor VIIa (FVIIa) is routinely used as an effective bypassing agent to treat hemophilia patients with inhibitory antibodies that compromise factor replacement. However, the mechanism by which FVIIa binds activated platelets to promote hemostasis is not fully understood. FVIIa-DVQ is an analog of FVIIa with enhanced tissue factor (TF)-independent activity and hemostatic efficacy relative to FVIIa. Our previous studies have shown that FVIIa-DVQ exhibits greater platelet binding (...) protein C or an anti-EPCR antibody. This decreased binding results in a corresponding decrease in the activity of both molecules in FXa and thrombin generation assays. Enhanced binding to EPCR was sufficient to account for the increased platelet binding of FVIIa-DVQ compared with wild-type FVIIa. As EPCR protein expression has not previously been shown in platelets, we confirmed the presence of EPCR in platelets using immunofluorescence, flow cytometry, immunoprecipitation, and mass spectrometry

2018 Journal of Thrombosis and Haemostasis

334. Clinical effect of enoxaparin on international normalized ratio following hepato-pancreatico-biliary and gastroesophageal resection. (Abstract)

Clinical effect of enoxaparin on international normalized ratio following hepato-pancreatico-biliary and gastroesophageal resection. Enoxaparin inactivates factor Xa via a complex formed after binding to circulating anti-thrombin III. This mechanism is reported not to alter hemostatic measures such as clotting time, PT, or PTT. To date, no clinical trials have shown a causal relationship between the clinical/pharmacological effects of enoxaparin on international normalized ratio (INR). The aim

2018 Journal of Surgical Oncology

335. Extravascular coagulation in hematopoietic stem and progenitor cell regulation. Full Text available with Trip Pro

Extravascular coagulation in hematopoietic stem and progenitor cell regulation. The hemostatic system plays pivotal roles in injury repair, innate immunity, and adaptation to inflammatory challenges. We review the evidence that these vascular-protective mechanisms have nontraditional roles in hematopoietic stem cell (HSC) maintenance in their physiological bone marrow (BM) niches at steady-state and under stress. Expression of coagulation factors and the extrinsic coagulation initiator tissue (...) of CXCL12-CXCR4 niche retention signals. Protease-activated receptor 1-biased signaling by EPCR-aPC also maintains HSC retention, whereas thrombin signaling activates HSC motility and BM egress. Furthermore, HSC mobilization under stress is enhanced by the fibrinolytic and complement cascades that target HSCs and their BM niches. In addition, coagulation, fibrinolysis, and HSC-derived progeny, including megakaryocytes, synergize to reestablish functional perivascular HSC niches during BM stress

2018 Blood

336. Comparision Between Activated Partial Thromboplastin Time Versus Anti-Xa Activity in Heparin Monitoring

), particularly FXa and FIIa (thrombin) . Despite the growing interest for low molecular weight derivatives (LMWH), UFH is still widely used for different indications including the treatment of acute thrombosis including venous thromboembolism, coronary syndromes (ACS), and other thrombotic diseases. UFH is administered by parenteral route either intravenous (IV) or sub-cutaneous (SC).Actually, there is evidence that the risk of recurrence of thrombosis is increased when heparin levels fells below the lower (...) Molecular Mechanisms of Pharmacological Action Hemostatics Coagulants

2018 Clinical Trials

337. Better platelet function, less fibrinolysis and less hemolysis in re-transfused residual pump blood with the Ringer's chase technique - a randomized pilot study. (Abstract)

Better platelet function, less fibrinolysis and less hemolysis in re-transfused residual pump blood with the Ringer's chase technique - a randomized pilot study. Residual pump blood from the cardiopulmonary bypass (CPB) circuit is often collected into an infusion bag (IB) and re-transfused. An alternative is to chase the residual blood into the circulation through the arterial cannula with Ringer's acetate. Our aim was to assess possible differences in hemostatic blood quality between these two (...) were comparable with the two methods, as were soluble platelet activation markers P-selectin and soluble glycoprotein VI (GPVI). Platelet aggregation (U) in the IB blood was significantly lower compared to the RC blood, with the agonists adenosine diphosphate (ADP) 24 (10-32) vs 46 (33-65), p<0.01, thrombin receptor activating peptide (TRAP) 50 (29-73) vs 69 (51-92), p=0.04 and collagen 24 (17-28) vs 34 (26-59), p<0.01. The IB blood had higher amounts of free hemoglobin (mg/L) (1086 (891-1717) vs

2018 Perfusion Controlled trial quality: uncertain

338. Comparison of acute and convalescent biomarkers of inflammation in patients with acute pulmonary embolism treated with systemic fibrinolysis vs. placebo. (Abstract)

), myeloperoxidase (MPO)] and hemostatic [plasminogen activator inhibitor-1 (PAI-1), fibrinogen, thrombin-activatable fibrinolysis inhibitor and D-dimer] biomarkers were quantified. The median values of the biomarkers of inflammation (IL-6, CRP, MPO) were all significantly decreased at 3-month follow-up, ranging from a 60 to 91% reduction over this time period. Concentrations of PAI-1 and fibrinogen did not change significantly. D-dimer concentration at 3-month follow-up was lower in patients treated (...) Comparison of acute and convalescent biomarkers of inflammation in patients with acute pulmonary embolism treated with systemic fibrinolysis vs. placebo. : Previous studies have associated biomarkers indicative of acute inflammation with pulmonary embolism, which may amplify coagulation, inhibit fibrinolysis and increase risk of venous thromboembolism (VTE) recurrence. The aim of this study was to measure inflammatory and hemostatic biomarkers in acute submassive pulmonary embolism at diagnosis

2018 Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis Controlled trial quality: uncertain

339. Registry Study for the Use of HEMOBLASTâ„¢ Bellows in Abdominoplasty

to control minimal, mild, or moderate bleeding for which conventional means of hemostasis are ineffective or impractical Device: HEMOBLAST Bellows The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except (...) .: No Keywords provided by Biom'Up SA: Hemostatics Coagulants

2018 Clinical Trials

340. The multifaceted role of fibrinogen in tissue injury and inflammation. Full Text available with Trip Pro

The multifaceted role of fibrinogen in tissue injury and inflammation. The canonical role of the hemostatic and fibrinolytic systems is to maintain vascular integrity. Perturbations in either system can prompt primary pathological end points of hemorrhage or thrombosis with vessel occlusion. However, fibrin(ogen) and proteases controlling its deposition and clearance, including (pro)thrombin and plasmin(ogen), have powerful roles in driving acute and reparative inflammatory pathways that affect (...) to the identification of novel hemostatic factor-targeted therapies for a range of tissue injuries and disease.© 2019 by The American Society of Hematology.

2018 Blood

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>